Recent successes of Capstan and Verve on LNP safety have put the industry back in the spotlight and reignited hope that lipid nanoparticles can overcome the biggest hurdles in drug delivery. However, Intellia’s pause to its CRISPR trial following an FDA request for additional safety data serves as a reminder of how crucial it is to deepen our understanding of immunogenicity and toxicity in LNP delivery. 

The 4^th LNP Immunogenicity & Toxicity Summit returned in December 2025 as the only dedicated forum to stay ahead of emerging safety insights, benchmark pre-clinical and clinical strategies, and ensure your LNP programs are built for regulatory confidence and clinical success. 

The 2025 unmissable one-day virtual summit brought you the latest breakthroughs and real-world insights driving safer, smarter LNP development. Attendees deep dived into cutting-edge discussions spanning predictive and AI modelling, translational animal models, and PK/PD strategies designed to accelerate prediction, optimize dosing, and boost the clinical performance of pegylated and ionizable LNPs across all payloads. 

From headline sessions tackling the translational gap between preclinical and clinical findings, the next frontier in extrahepatic delivery, to regulatory guidance shaping the future of LNP approvals, and repeat dosing and PEGylation challenges that every program must overcome, this was a conversation not to miss.